Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)

Trial Profile

A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcabene (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms COBALT-1
  • Sponsors Gemphire Therapeutics
  • Most Recent Events

    • 26 Sep 2019 Results evaluating the safety and efficacy of gemcabene as an add on therapy to current lipid lowering regimens in patients with Homozygous Familial Hypercholesterolemia published in the American Journal of Cardiology
    • 25 Sep 2017 The complete data from this study will also be submitted for publication in a peer reviewed journal, according to a Gemphire Therapeutics media release
    • 25 Sep 2017 According to a Gemphire Therapeutics media release, the company is planning to share data from this study with the FDA and EMA in end of Phase 2 meetings.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top